Snapshot · Vertex Pharmaceuticals Incorporated (VRTX)

Data as of 2026-10-19T01:33:48.785Z

Fundamentals check

Market cap

$126.7B

P/E (TTM)

28.9

Gross margin

86.0%

Net margin

34.9%

ROE

23.3%

R&D / revenue

31.4%

Dividend yield

0.0%

FCF yield

3.0%

Summary

Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.

How it makes money

Revenue mix, latest fiscal year

• TRIKAFTA/KAFTRIO86.2%
• ALYFTREK7%
• Manufactured Product, Other6.9%

Recent Events

• 2026-10-13T00:00:00.000Znegative

  Price move: VRTX fell 4.3%

  VRTX 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-10-09T20:50:03.000Zpositive

  Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know

  可能与市场整体走强相关，提示投资者需关注但不构成确定性因果。

  Source: Zacks Investment Research

• 2026-10-09T13:15:00.000Zneutral

  Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference

  恰逢新数据公布，可能对未来前景有帮助，但短期影响存在不确定性。

  Source: businesswire.com

• 2026-10-07T16:00:00.000Zneutral

  Vertex to Announce Third Quarter 2026 Financial Results November 2nd

  恰逢财报日临近，潜在影响尚不确定，可能影响投资者情绪但非直接因果。

  Source: businesswire.com

• 2026-09-10T04:17:05.000Znegative

  Vertex Pharmaceuticals Incorporated (VRTX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

  可能与股价在短期内下行压力相关，恰逢会议披露信息，无法确认因果关系。

  Source: seekingalpha.com

• 2026-09-08T00:00:00.000Znegative

  Price move: VRTX fell 3.2%

  VRTX 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-08-29T04:12:00.000Znegative

  17,047 Shares in Vertex Pharmaceuticals Incorporated $VRTX Acquired by Beacon Pointe Advisors LLC

  可能与机构持仓变化相关，但不能断言驱动股价走弱的直接原因，属于市场反应的一部分。

  Source: defenseworld.net

• 2026-08-19T00:00:00.000Zpositive

  Price move: VRTX rose 4.5%

  VRTX 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-08-10T00:00:00.000Zpositive

  Price move: VRTX rose 5.6%

  VRTX 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

Analyst view

Avg price target $590.69 from 13 analysts (last quarter)

Insider & Congress activity

订阅每日简报

每个交易日开盘/收盘后，中文市场简报直达邮箱。免费，随时退订。

本内容仅为信息整理，不构成任何投资建议。